A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
23actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-27 | actual | When the study began enrolling |
| Primary completion | 2025-07-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prurigo Nodularis
Intervention
- Drug: Ruxolitinib Cream 1.5%
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 16 weeks, including 30 days of safety follow-up
Number of participants with TEAEs leading to dose interruption or discontinuation
measured Up to 16 weeks, including 30 days of safety follow-up
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed